Last updated on August 2019

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.


Brief description of study

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease (AD).

Detailed Study Description

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease (AD).

This Phase 2 study is designed to evaluate the safety of two doses of CT1812 administered once daily for 6 months in adults aged 50 to 85 who have been diagnosed with mild to moderate Alzheimer's disease (the targeted clinical indication for CT1812). Randomized participants will receive 100 mg of CT1812, 300 mg of CT1812, or placebo once daily for 182 days. Exploratory endpoints that evaluate the effect of CT1812 on biomarkers are also included.

Clinical Study Identifier: NCT03507790

Find a site near you

Start Over

Melbourne Health

Parkville, Australia
1.71miles
  Connect »

Alfred Health

Melbourne, Australia
3.3miles
  Connect »

Austin Health

Ivanhoe, Australia
6.99miles
  Connect »

St Vincent's Hospital Sydney

Ivanhoe, Australia
6.99miles
  Connect »